in this issue
Regions :: India/Pakistan
Aurobindo Pharma’s API business reports rise in sales, targets annual API sales of $700 million by 2016
5:31 AM MDT | August 20, 2013 | Deepti Ramesh
The active pharmaceutical ingredients (API) business of Aurobindo Pharma (Hyderabad, India) reports a 10.2% rise in sales, to 6.46 billion Indian rupees ($101 million), in the fiscal first quarter, ended 30 June, compared with the year-ago quarter. Cephalosporin accounted for Rs2.16 billion of the total API sales in the first quarter, semisynthetic penicillin (SSP) accounted for Rs2.22 billion, and nonbetalactam accounted for Rs2.08 billion. Earnings figures for the API business have not been disclosed. Aurobindo Pharma manufactures generic pharmaceuticals...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee